Research ExplorerPublicationsIxazomib-Thalidomide-Dexamethasone for induction therapy fol...

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

Standard

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. / Ludwig, Heinz; Poenisch, Wolfram; Knop, Stefan; Egle, Alexander; Schreder, Martin; Lechner, Daniel; Hajek, Roman; Gunsilius, Eberhard; Krenosz, Karl Jochen; Petzer, Andreas; Weisel, Katja; Niederwieser, Dietger; Einsele, Hermann; Willenbacher, Wolfgang; Melchardt, Thomas; Greil, Richard; Zojer, Niklas.

In: BRIT J CANCER, Vol. 121, No. 9, 10.2019, p. 751-757.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ludwig, H, Poenisch, W, Knop, S, Egle, A, Schreder, M, Lechner, D, Hajek, R, Gunsilius, E, Krenosz, KJ, Petzer, A, Weisel, K, Niederwieser, D, Einsele, H, Willenbacher, W, Melchardt, T, Greil, R & Zojer, N 2019, 'Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma', BRIT J CANCER, vol. 121, no. 9, pp. 751-757. https://doi.org/10.1038/s41416-019-0581-8

APA

Ludwig, H., Poenisch, W., Knop, S., Egle, A., Schreder, M., Lechner, D., Hajek, R., Gunsilius, E., Krenosz, K. J., Petzer, A., Weisel, K., Niederwieser, D., Einsele, H., Willenbacher, W., Melchardt, T., Greil, R., & Zojer, N. (2019). Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. BRIT J CANCER, 121(9), 751-757. https://doi.org/10.1038/s41416-019-0581-8

Vancouver

Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D et al. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. BRIT J CANCER. 2019 Oct;121(9):751-757. https://doi.org/10.1038/s41416-019-0581-8

Bibtex

@article{e947b5c1bb374cb285c9ad1e93c7ab07,
title = "Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma",
abstract = "BACKGROUND: Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients.METHODS: Ninety patients have been included. Ixazomib-thalidomide-dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) was scheduled for eight cycles followed by maintenance with ixazomib for one year.RESULTS: The overall response rate was 51.1%, 23.3% achieved CR or VGPR and 10% MR resulting in a clinical benefit rate of 61.1%. In patients completing ≥2 cycles, the rates were 60.5%, 27.6% and 68.4%, respectively. Median progression-free survival (PFS) was 8.5 months in all, and 9.4 months in those completing ≥2 cycles. Response rates, PFS and overall survival (OS) were similar in patients with and without t(4;14) and/or del(17p), but PFS and OS was significantly shorter in patients with gain of 1q21. Multivariate regression analysis revealed gain of 1q21 as the most important factor associated with OS. Ixazomib maintenance resulted in an upgrade in the depth of response in 12.4% of patients. Grade 3/4 toxicities were relatively rare.CONCLUSIONS: Ixazomib-thalidomide-dexamethasone followed by ixazomib maintenance therapy is active and well tolerated in patients with RRMM.TRIAL REGISTRATION NUMBER: NCT02410694.",
author = "Heinz Ludwig and Wolfram Poenisch and Stefan Knop and Alexander Egle and Martin Schreder and Daniel Lechner and Roman Hajek and Eberhard Gunsilius and Krenosz, {Karl Jochen} and Andreas Petzer and Katja Weisel and Dietger Niederwieser and Hermann Einsele and Wolfgang Willenbacher and Thomas Melchardt and Richard Greil and Niklas Zojer",
year = "2019",
month = oct,
doi = "10.1038/s41416-019-0581-8",
language = "English",
volume = "121",
pages = "751--757",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "9",

}

RIS

TY - JOUR

T1 - Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

AU - Ludwig, Heinz

AU - Poenisch, Wolfram

AU - Knop, Stefan

AU - Egle, Alexander

AU - Schreder, Martin

AU - Lechner, Daniel

AU - Hajek, Roman

AU - Gunsilius, Eberhard

AU - Krenosz, Karl Jochen

AU - Petzer, Andreas

AU - Weisel, Katja

AU - Niederwieser, Dietger

AU - Einsele, Hermann

AU - Willenbacher, Wolfgang

AU - Melchardt, Thomas

AU - Greil, Richard

AU - Zojer, Niklas

PY - 2019/10

Y1 - 2019/10

N2 - BACKGROUND: Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients.METHODS: Ninety patients have been included. Ixazomib-thalidomide-dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) was scheduled for eight cycles followed by maintenance with ixazomib for one year.RESULTS: The overall response rate was 51.1%, 23.3% achieved CR or VGPR and 10% MR resulting in a clinical benefit rate of 61.1%. In patients completing ≥2 cycles, the rates were 60.5%, 27.6% and 68.4%, respectively. Median progression-free survival (PFS) was 8.5 months in all, and 9.4 months in those completing ≥2 cycles. Response rates, PFS and overall survival (OS) were similar in patients with and without t(4;14) and/or del(17p), but PFS and OS was significantly shorter in patients with gain of 1q21. Multivariate regression analysis revealed gain of 1q21 as the most important factor associated with OS. Ixazomib maintenance resulted in an upgrade in the depth of response in 12.4% of patients. Grade 3/4 toxicities were relatively rare.CONCLUSIONS: Ixazomib-thalidomide-dexamethasone followed by ixazomib maintenance therapy is active and well tolerated in patients with RRMM.TRIAL REGISTRATION NUMBER: NCT02410694.

AB - BACKGROUND: Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients.METHODS: Ninety patients have been included. Ixazomib-thalidomide-dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) was scheduled for eight cycles followed by maintenance with ixazomib for one year.RESULTS: The overall response rate was 51.1%, 23.3% achieved CR or VGPR and 10% MR resulting in a clinical benefit rate of 61.1%. In patients completing ≥2 cycles, the rates were 60.5%, 27.6% and 68.4%, respectively. Median progression-free survival (PFS) was 8.5 months in all, and 9.4 months in those completing ≥2 cycles. Response rates, PFS and overall survival (OS) were similar in patients with and without t(4;14) and/or del(17p), but PFS and OS was significantly shorter in patients with gain of 1q21. Multivariate regression analysis revealed gain of 1q21 as the most important factor associated with OS. Ixazomib maintenance resulted in an upgrade in the depth of response in 12.4% of patients. Grade 3/4 toxicities were relatively rare.CONCLUSIONS: Ixazomib-thalidomide-dexamethasone followed by ixazomib maintenance therapy is active and well tolerated in patients with RRMM.TRIAL REGISTRATION NUMBER: NCT02410694.

U2 - 10.1038/s41416-019-0581-8

DO - 10.1038/s41416-019-0581-8

M3 - SCORING: Journal article

C2 - 31558804

VL - 121

SP - 751

EP - 757

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 9

ER -